Sökning: L773:0041 1132
> Kjeldsen Kragh Jens >
Risk of HPA-1a–immu...
Risk of HPA-1a–immunization in HPA-1a–negative women after giving birth to an HPA-1a–positive child
-
- Kjeldsen-Kragh, Jens (författare)
- Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Regional Laboratories Region Skåne,University Hospital of North Norway
-
- Olsen, Klaus Juel (författare)
- Larix A/S
-
(creator_code:org_t)
- 2019-02-06
- 2019
- Engelska.
-
Ingår i: Transfusion. - : Wiley. - 0041-1132 .- 1537-2995. ; 59:4, s. 1344-1352
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is the platelet counterpart of hemolytic disease of the newborn. Most severe cases of FNAIT are caused by antibodies against human platelet antigen-1a (HPA-1a). HPA-1a–negative women giving birth to an HPA-1a–positive child are at risk of becoming HPA-1a–immunized, particularly women who are HLA-DRB3*01:01–positive. The aim of the study was to estimate the risk of HPA-1a–immunization in both HPA-1a–negative/HLA-DRB3*01:01–positive and HPA-1a–negative/HLA-DRB3*01:01–negative women after delivery of an HPA-1a–positive child. STUDY DESIGN AND METHODS: A literature search was conducted, which identified 10 prospective FNAIT studies. The risk of becoming HPA-1a–immunized postpartum was calculated by Bayes' theorem. The results of HLA-DRB3/4/5 typing of 212,472 European Caucasians from the National Marrow Donor Program were used as estimate of the frequency of the HLA-DRB3*01:01 allele. RESULTS: In HPA-1a–negative/HLA-DRB3*01:01–positive women, the risk of HPA-1a–immunization after delivery of an HPA-1a–positive child was estimated to 12.7% (95% confidence interval, 8.6%–16.8%) as compared to 0.5% (95% confidence interval, 0.1%–0.9%) in women who were HLA-1a–negative/HLA-DRB3*01:01–negative. Potential differences between nulliparous and multiparous and the role of one versus two doses of HLA-DRB3*01:01 could not be determined. CONCLUSION: In HPA-1a–negative/HLA-DRB3*01:01–positive women, the risk of HPA-1a–immunization is 12.7% after delivery of an HPA-1a–positive child, which is 25 times higher than in HPA-1a–negative/HLA-DRB3*01:01–negative women. Thus, the risk of HPA-1a–immunization in high-risk pregnancies is in the same range as the risk of RhD immunization in RhD-negative women after delivery of a RhD-positive child without RhD prophylaxis.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas